XNYS
CAH
Market cap55bUSD
Oct 08, Last price
238.96USD
1D
2.93%
1Q
1.34%
Jan 2017
232.03%
Name
Cardinal Health Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cardinal Health, Inc. functions as a comprehensive provider of healthcare services and products, extending its reach across the United States, Canada, Europe, Asia, and other international markets. The company delivers tailored solutions to a diverse client base, encompassing hospitals, healthcare systems, pharmacies, outpatient surgical centers, clinical testing facilities, physician's offices, and individuals receiving care at home. Its operations are bifurcated into two principal divisions: Pharmaceutical and Medical. The Pharmaceutical division is responsible for the distribution of a broad spectrum of pharmaceuticals, including proprietary and generic medications, specialty drugs, and over-the-counter health items. It further extends its services to pharmaceutical manufacturers and healthcare providers, specifically supporting specialized pharmaceutical products. This segment also manages nuclear pharmacies and facilities for radiopharmaceutical production, in addition to repackaging generic and OTC health products. Moreover, it delivers medication therapy management and patient outcomes improvement services to hospitals, various healthcare practitioners, and insurers, alongside providing comprehensive pharmacy management for hospitals. The Medical division concentrates on the manufacturing, procurement, and distribution of Cardinal Health's proprietary range of medical, surgical, and laboratory equipment and supplies. This extensive product portfolio features items such as examination and surgical gloves; needles, syringes, and sharps disposal units; compression wear; incontinence supplies; nutritional delivery systems; wound care products; single-use surgical drapes, gowns, and apparel; fluid suction and collection apparatus; urological supplies; operating room essentials; and electrode product lines. Furthermore, this segment distributes a wide array of nationally recognized medical, surgical, and laboratory products. It also offers critical supply chain services and solutions to hospitals, outpatient surgical centers, clinical laboratories, and other healthcare providers, while also producing and selling pre-assembled sterile and non-sterile procedure kits. Established in 1979, Cardinal Health maintains its corporate headquarters in Dublin, Ohio.
Related entities
Subsidiaries (6)
Cardinal Health 250 Dutch C.V.
CARDINAL HEALTH FINANCE
CARDINAL HEALTH IRELAND UNLIMITED COMPANY
CARDINAL HEALTH MALTA 212 LIMITED
CARDINAL HEALTH NETHERLANDS 502 B.V.
CARDINAL HEALTH SWITZERLAND 515 GMBH
Key people
Non-Executive Chairman of the Board · since 2018
Chief Executive Officer, Director · since 2019
Chief Financial Officer · since 2020
Victor L. Crawford
Chief Executive Officer - Pharmaceutical segment · since 2018
Stephen M. Mason
Chief Executive Officer-Medical Segment · since 2019
Ola M. Snow
Chief Human Resource Officer · since 2018
Executive Vice President, Chief Information Officer and Customer Support Services · since 2019
Jessica L. Mayer
Chief Legal and Compliance Officer · since 2019
Independent Director · since 2007
Independent Director · since 2009
Bruce L. Downey
Independent Director · since 2009
Independent Director · since 2018
Independent Director · since 2015
Independent Director · since 2018
Dean A. Scarborough
Independent Director · since 2019
John H. Weiland
Independent Director · since 2019
IPO date
Aug 04, 1983
Employees
47,040
Domiciled in
US
Incorporated in
US
Legal address
C/O CT CORPORATION SYSTEM
4400 EASTON COMMONS WAY
SUITE 125
COLUMBUS, OH 43219
US
4400 EASTON COMMONS WAY
SUITE 125
COLUMBUS, OH 43219
US
Headquarters
7000 Cardinal Place
Dublin, OH 43017
US
Dublin, OH 43017
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑07 | 2026‑06 | 2025‑12 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||